183 related articles for article (PubMed ID: 37636077)
1. Gene signature reveals decreased SOX10-dependent transcripts in malignant cells from immune checkpoint inhibitor-resistant cutaneous melanomas.
Purwin TJ; Caksa S; Sacan A; Capparelli C; Aplin AE
iScience; 2023 Sep; 26(9):107472. PubMed ID: 37636077
[TBL] [Abstract][Full Text] [Related]
2. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma.
Capparelli C; Purwin TJ; Glasheen M; Caksa S; Tiago M; Wilski N; Pomante D; Rosenbaum S; Nguyen MQ; Cai W; Franco-Barraza J; Zheng R; Kumar G; Chervoneva I; Shimada A; Rebecca VW; Snook AE; Hookim K; Xu X; Cukierman E; Herlyn M; Aplin AE
Nat Commun; 2022 Mar; 13(1):1381. PubMed ID: 35296667
[TBL] [Abstract][Full Text] [Related]
3. Sox10-Deficient Drug-Resistant Melanoma Cells Are Refractory to Oncolytic RNA Viruses.
Abou-Hamad J; Hodgins JJ; Yakubovich E; Vanderhyden BC; Ardolino M; Sabourin LA
Cells; 2023 Dec; 13(1):. PubMed ID: 38201278
[TBL] [Abstract][Full Text] [Related]
4. SOX10 Inhibits T Cell Recognition by Inducing Expression of the Immune Checkpoint Molecule PD-L1 in A375 Melanoma Cells.
Sasaki K; Hirohashi Y; Murata K; Minowa T; Nakatsugawa M; Murai A; Mizue Y; Kubo T; Kanaseki T; Tsukahara T; Iwabuchi S; Hashimoto S; Uhara H; Ishida-Yamamoto A; Torigoe T
Anticancer Res; 2023 Apr; 43(4):1477-1484. PubMed ID: 36974807
[TBL] [Abstract][Full Text] [Related]
5. SOX10 Knockdown Inhibits Melanoma Cell Proliferation via Notch Signaling Pathway.
Tang Y; Cao Y
Cancer Manag Res; 2021; 13():7225-7234. PubMed ID: 34557039
[TBL] [Abstract][Full Text] [Related]
6. MEK inhibition remodels the active chromatin landscape and induces SOX10 genomic recruitment in BRAF(V600E) mutant melanoma cells.
Fufa TD; Baxter LL; Wedel JC; Gildea DE; ; Loftus SK; Pavan WJ
Epigenetics Chromatin; 2019 Aug; 12(1):50. PubMed ID: 31399133
[TBL] [Abstract][Full Text] [Related]
7. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
Front Immunol; 2022; 13():955063. PubMed ID: 36248850
[TBL] [Abstract][Full Text] [Related]
8. Temporal activation of WNT/β-catenin signaling is sufficient to inhibit SOX10 expression and block melanoma growth.
Uka R; Britschgi C; Krättli A; Matter C; Mihic D; Okoniewski MJ; Gualandi M; Stupp R; Cinelli P; Dummer R; Levesque MP; Shakhova O
Oncogene; 2020 May; 39(20):4132-4154. PubMed ID: 32238882
[TBL] [Abstract][Full Text] [Related]
9. p300 KAT regulates SOX10 stability and function in human melanoma.
Waddell A; Grbic N; Leibowitz K; Wyant WA; Choudhury S; Park K; Collard M; Cole PA; Alani RM
bioRxiv; 2024 Feb; ():. PubMed ID: 38469149
[TBL] [Abstract][Full Text] [Related]
10. Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma.
Reschke R; Yu J; Flood B; Higgs EF; Hatogai K; Gajewski TF
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593622
[TBL] [Abstract][Full Text] [Related]
11. SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis.
Yokoyama S; Takahashi A; Kikuchi R; Nishibu S; Lo JA; Hejna M; Moon WM; Kato S; Zhou Y; Hodi FS; Song JS; Sakurai H; Fisher DE; Hayakawa Y
Cancer Res; 2021 Dec; 81(24):6131-6141. PubMed ID: 34728538
[TBL] [Abstract][Full Text] [Related]
12. Stringent comparative sequence analysis reveals SOX10 as a putative inhibitor of glial cell differentiation.
Gopinath C; Law WD; Rodríguez-Molina JF; Prasad AB; Song L; Crawford GE; Mullikin JC; Svaren J; Antonellis A
BMC Genomics; 2016 Nov; 17(1):887. PubMed ID: 27821050
[TBL] [Abstract][Full Text] [Related]
13. Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma.
Yeon M; Kim Y; Jung HS; Jeoung D
Front Cell Dev Biol; 2020; 8():486. PubMed ID: 32626712
[TBL] [Abstract][Full Text] [Related]
14. SOX10/keratin dual-color immunohistochemistry: An effective first-line test for the workup of epithelioid malignant neoplasms in FNA and small biopsy specimens.
Mito JK; Conner JR; Hornick JL; Cibas ES; Qian X
Cancer Cytopathol; 2018 Mar; 126(3):179-189. PubMed ID: 29385322
[TBL] [Abstract][Full Text] [Related]
15. Identification and functional analysis of SOX10 phosphorylation sites in melanoma.
Cronin JC; Loftus SK; Baxter LL; Swatkoski S; Gucek M; Pavan WJ
PLoS One; 2018; 13(1):e0190834. PubMed ID: 29315345
[TBL] [Abstract][Full Text] [Related]
16. UBE2N Promotes Melanoma Growth via MEK/FRA1/SOX10 Signaling.
Dikshit A; Jin YJ; Degan S; Hwang J; Foster MW; Li CY; Zhang JY
Cancer Res; 2018 Nov; 78(22):6462-6472. PubMed ID: 30224375
[TBL] [Abstract][Full Text] [Related]
17. Expression of Sox10 and c-kit in sinonasal mucosal melanomas arising in the Chinese population.
Liu HG; Kong MX; Yao Q; Wang SY; Shibata R; Yee H; Martiniuk F; Wang BY
Head Neck Pathol; 2012 Dec; 6(4):401-8. PubMed ID: 22736149
[TBL] [Abstract][Full Text] [Related]
18. Sox10 controls migration of B16F10 melanoma cells through multiple regulatory target genes.
Seong I; Min HJ; Lee JH; Yeo CY; Kang DM; Oh ES; Hwang ES; Kim J
PLoS One; 2012; 7(2):e31477. PubMed ID: 22363655
[TBL] [Abstract][Full Text] [Related]
19. SOX10 expression in superficial spreading and nodular malignant melanomas.
Agnarsdóttir M; Sooman L; Bolander A; Strömberg S; Rexhepaj E; Bergqvist M; Ponten F; Gallagher W; Lennartsson J; Ekman S; Uhlen M; Hedstrand H
Melanoma Res; 2010 Dec; 20(6):468-78. PubMed ID: 20890226
[TBL] [Abstract][Full Text] [Related]
20. A newly developed mouse monoclonal SOX10 antibody is a highly sensitive and specific marker for malignant melanoma, including spindle cell and desmoplastic melanomas.
Tacha D; Qi W; Ra S; Bremer R; Yu C; Chu J; Hoang L; Robbins B
Arch Pathol Lab Med; 2015 Apr; 139(4):530-6. PubMed ID: 25436903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
